Mostrar el registro sencillo del ítem
| dc.contributor.author | Di-Pierdomenico, Johnny | |
| dc.contributor.author | Gallego-Ortega, Alejandro | |
| dc.contributor.author | Norte-Muñoz, María | |
| dc.contributor.author | Vidal-Villegas, Beatriz | |
| dc.contributor.author | Bravo, Isaac | |
| dc.contributor.author | Boluda-Ruiz, María | |
| dc.contributor.author | Bernal-Garro, José-Manuel | |
| dc.contributor.author | Fernández-Bueno, Iván | |
| dc.contributor.author | Pastor-Jimeno, José-Carlos | |
| dc.contributor.author | Villegas-Pérez, María-Paz | |
| dc.contributor.author | Avilés-Trigueros, Marcelino | |
| dc.contributor.author | de-los-Ríos, Cristóbal | |
| dc.contributor.author | Vidal-Sanz, Manuel | |
| dc.date.accessioned | 2025-11-21T08:46:56Z | |
| dc.date.available | 2025-11-21T08:46:56Z | |
| dc.date.issued | 2024-02 | |
| dc.identifier.citation | Di Pierdomenico J, Gallego-Ortega A, Norte-Muñoz M, Vidal-Villegas B, Bravo I, Boluda-Ruiz M, et al. Evaluation of the neuroprotective efficacy of the gramine derivative ITH12657 against NMDA-induced excitotoxicity in the rat retina. Front Neuroanat. 13 de febrero de 2024;18:1335176. | |
| dc.identifier.issn | 1662-5129 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21999 | |
| dc.description.abstract | PURPOSE: The aim of this study was to investigate, the neuroprotective effects of a new Gramine derivative named: ITH12657, in a model of retinal excitotoxicity induced by intravitreal injection of NMDA. METHODS: Adult Sprague Dawley rats received an intravitreal injection of 100 mM NMDA in their left eye and were treated daily with subcutaneous injections of ITH12657 or vehicle. The best dose-response, therapeutic window study, and optimal treatment duration of ITH12657 were studied. Based on the best survival of Brn3a + RGCs obtained from the above-mentioned studies, the protective effects of ITH12657 were studied in vivo (retinal thickness and full-field Electroretinography), and ex vivo by quantifying the surviving population of Brn3a + RGCs, ?RGCs and their subtypes ?-ONsRGCs, ?-ONtRGCs, and ?-OFFRGCs. RESULTS: Administration of 10 mg/kg ITH12657, starting 12 h before NMDA injection and dispensed for 3 days, resulted in the best significant protection of Brn3a + RGCs against NMDA-induced excitotoxicity. In vivo, ITH12657-treated rats showed significant preservation of retinal thickness and functional protection against NMDA-induced retinal excitotoxicity. Ex vivo results showed that ITH12657 afforded a significant protection against NMDA-induced excitotoxicity for the populations of Brn3a + RGC, ?RGC, and ?ONs-RGC, but not for the population of ?OFF-RGC, while the population of ?-ONtRGC was fully resistant to NMDA-induced excitotoxicity. CONCLUSION: Subcutaneous administration of ITH12657 at 10 mg/kg, initiated 12 h before NMDA-induced retinal injury and continued for 3 days, resulted in the best protection of Brn3a + RGCs, ?RGC, and ?ONs-RGC against excitotoxicity-induced RGC death. The population of ?OFF-RGCs was extremely sensitive while ?-ONtRGCs were fully resistant to NMDA-induced excitotoxicity. | |
| dc.language.iso | eng | |
| dc.publisher | FRONTIERS MEDIA SA | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/es/ | * |
| dc.title | Evaluation of the neuroprotective efficacy of the gramine derivative ITH12657 against NMDA-induced excitotoxicity in the rat retina | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 38415017 | |
| dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fnana.2024.1335176/full | |
| dc.identifier.doi | 10.3389/fnana.2024.1335176 | |
| dc.journal.title | Frontiers in Neuroanatomy |